Company Also Readies Imminent Appeal in The Johnson & Johnson Patent Infringement Matter With The U.S. Court Of Appeals for The Federal Circuit
LOS ANGELES, CA – December 17, 2018 Decision Diagnostics Corp. (OTC: DECN) Decision Diagnostics Corp. is a 16 year olddiabetes focused bio-technology R&D firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for a growing brand of glucose test strips and meters as highly accurate alternatives for legacy diabetic, proprietary, and pet testing glucose test strips. The company’s current portfolio of test strips includes its GenUltimate!, GenChoice!, GenSure!, and GenUltimate! TBG test strips, its Avantage! and Precise! Glucometers, and its PetSure! and GenUltimate! 4Pets testing products for dogs, cats and horses.
Decision Diagnostics is pleased to announce that as of February 1, 2019 the company will bring on an additional contract manufacturer in Korea with additional manufacturing capacity to handle the company’s existing products as well as its new products. As stated on December 11, DECN has realigned its product technologies into two tool-boxes, a GenUltimate! technologies tool-box, which includes the company’s GenUltimate!, GenUltimate! 4Pets, GenSure! and GenUltimate! TBG test strip products, as well as a GenChoice! technologies toolbox, which includes the company’s GenChoice!, PetSure! and an as yet unannounced new legacy test strip alternative. The new ISO-approved manufacturing facility in Korea will have two manufacturing lines, each line with the capacity of 1 million units (boxes) annually.
Keith Berman, CEO of Decision Diagnostics Corp. stated, “We have been in negotiation with our latest partner for a number of months, waiting for their contracts with other firms to come to term in a manner that allows DECN to take full advantage of this larger facility. The new facility, located just outside of Seoul, Korea will not require additional large capital investment and only minimal tooling change.”
On a separate note, the company also announced that they are in the process of applying for and receiving additional small business registration status with the U.S. FDA. This status will further facilitate the filing of the 510K application for the company’s GenChoice! product.”
Mr. Berman concluded, “We will have an additional discussion in the coming days that will cover important details about our 2019 products and development plans as discussed in our December 11, 2018 news release. But we also plan an announcement in the next several days about our appeal in the Johnson and Johnson patent infringement case. This appeal will be filed imminently. We anticipate the Court of Appeals to again come to a Precedential ruling in this matter.”
ABOUT DECISION DIAGNOSTICS CORP
Decision Diagnostics Corp. is the leading manufacturer and worldwide distributor of diabetic test strips engineered to operate on legacy glucose meters. DECN’s products are designed to operate efficiently and less expensively on certain glucose meters already in use by almost 7.5 million diabetics worldwide. With new inspired technology diabetic test strips already in the final stages of development, DECN products compete on a worldwide scale with legacy manufacturers currently selling to 71+ percent of a $12 billion at-home testing market.
Forward-Looking Statements
This release contains the company’s forward-looking statements which are based on management’s current expectations and assumptions as of December 14, 2018, regarding the company’s business and performance, its prospects, current factors, the economy, and other future conditions and forecasts of future events, circumstances, and results.
